Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.